Skip to main content
SpringerLink
Log in

Thrombolysetherapie des akuten Herzinfarktes

  • Chapter
Notfallbehandlung des akuten Koronarsyndroms

  • 43 Accesses

Zusammenfassung

Berücksichtigt man ausschlieβlich die Daten groβer randomisierter Letalitätsstudien, so scheint der akute Myokardinfarkt dank der modernen Medizin seinen Schrecken weitgehend verloren zu haben [1–3]. Trotz tendenziellem Rückgang in den letzten 20 Jahren stellt der akute Herzinfarkt jedoch auch heute noch eine der häufigsten Todesursachen dar [4–6]. Fast die Hälfte der Betroffenen verstirbt in der Akutphase bereits vor dem Eintreffen medizinischer Hilfe am arrhythmogenen Sekundenherztod, aber auch wenn die Patienten ein Krankenhaus erreichen, liegt die Gesamtsterblichkeit weiterhin - im Gegensatz zu den Daten multizentrischer Studien - bei mehr als 15–20% [4,6]. Da die verbleibende Myokardfunktion den primären Indikator für die Langezeitprognose der Infarktpatienten darstellt [7], sind die therapeutischen Bemühungen heute auf den Erhalt des Myokards gerichtet.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. den Heijer P, Verrneer F, Ambrosioni E et al. on behalf of the In TIME Investigators (1998) Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction. A double-blind, randomized angiographic trial of Lanoteplase versus Alteplase. Circulation 98:2117–2125

    Article  Google Scholar 

  2. Assesment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators (1999) Comparison of a single-bolus Tenecteplase with accelerated infusion of Alteplase in acute myocardial infarction. The double blind, randomised ASSENT-2 study. Lancet 254:716–722

    Google Scholar 

  3. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators (1997) A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337:1118–1123

    Article  Google Scholar 

  4. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mähönen M, Cepaitis Z, Kuulasmaa K, Keil U for the WHO MONICA Project (2000) Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA project populations. Lancet 355:688–700

    Article  PubMed  CAS  Google Scholar 

  5. Löwel H, Lewis M, Keil U, Hörmann A, Bolte H-D, Willich S, Gostomzyk J (1995) Zeitliche Trends von Herzinfarktmorbidität, -mortalität, 28-Tage-Letalität und medizinischer Versorgung - Ergebnisse des Augsburger Herzinfarktregisters von 1985 bis 1992. Z Kardiol 84:596–605

    PubMed  Google Scholar 

  6. Löwel H, Lewis M, Keil U, Koenig W, Hörmann A, Bolte H-D, Gostomzyk J (1985) Zur Herzinfarktsituation in der süddeutschen Bevölkerung: Ergebnisse des Augsburger Herzinfarktregisters. Z Kardiol 1988 77:481–489

    Google Scholar 

  7. Bigger JT Jr (1985) Risk stratification after myocardial infarction. Z Kardiol 74 [Suppl 6]:147–157

    PubMed  Google Scholar 

  8. Davies MJ, Thomas AC (1985) Plaque fissuring - The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 53:363–373

    Article  PubMed  CAS  Google Scholar 

  9. Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671

    Article  PubMed  CAS  Google Scholar 

  10. Fuster V, Stein B, Badimon L, Badimon JJ, Ambrose JA, Chesebro JH (1990) Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 82 [Suppl 11]:11–47–II–59

    Google Scholar 

  11. Farb A, Burke AP, Tang AL, Liang Y, Mannan P, Smialek J, Virmani R (1996) Coronary plaque errosion withiout rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93:1354–1363

    Article  PubMed  CAS  Google Scholar 

  12. Virmani R, Kolodigie FD, Burke AP, Farb A, Schwarz SM (2000) Lessons from sudden death. A comprehensive morphological classification scheme for arteriosclerotic lesions. Arterioscler Thromb Vase Biol 20:1262–1275

    Article  CAS  Google Scholar 

  13. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB (1977) The wavefront phenomenon of ischemic cell death. I. myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 56:786–794

    Article  PubMed  CAS  Google Scholar 

  14. Karsch KR, Hofmann M, Rentrop KP, Schaper W (1983) Thrombolysis in acute experimental myocardial infarction. JACC 1:427–435

    Article  PubMed  CAS  Google Scholar 

  15. Schaper J (1986) Ultrastructural aspects of ischemia and reperfusion in canine and human hearts. In: Effert S, Essen R von, Hugenholtz PG, Uebis R, Verstraete M (Hrsg) Facts and hopes in thrombolysis in acute myocardial infarction. Steinkopf, Darmstadt, S 7–18

    Google Scholar 

  16. Cigarroa RG, Lange RA, Hillis D (1989) Prognosis after acute myocardial infarction in patients with and without residual antegrade coronary flow. Am J Cardiol 64:155–160

    Article  PubMed  CAS  Google Scholar 

  17. Trappe HJ, Lichtlen PR, Klein H, Wenzlaff P, Hartwig CA (1989) Natural history of single vessel disease. Risk of sudden coronary death in relation to coronary anatomy and arrhythmia profile. Eur Heart J 10:514–524

    PubMed  CAS  Google Scholar 

  18. Braunwald E (1989) Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation 79/2:441–444

    Article  Google Scholar 

  19. Popovic AD, Neskovic AN, Babic R et al. (1994) Independent impact of thrombolytic therapy and vessel patency on left ventricular dilation after myocardial infarction. Circulation 90:800–807

    Article  PubMed  CAS  Google Scholar 

  20. Gulba DC, Westhoff-Bleck M, Reil GH (1990) Thrombolysetherapie des akuten Herzinfarktes - Ergebnisse und neue Entwicklungen. Dtsch Med Wochenschr 115:187–195

    Article  PubMed  CAS  Google Scholar 

  21. Boersma E, Maas A, Deckers J, Simoons M (1996) Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 348:771–775

    Article  PubMed  CAS  Google Scholar 

  22. Weaver WD, Cerqueira M, Hallstorm AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M, for the Myocardial Infarction Triage and Intervention Project Group (1993) Prehospital-initiated vs hospital initiated thrombolytic therapy - The myocardial infarction triage and intervention trial. J Am Med Assoc 270:1211–1216

    Article  CAS  Google Scholar 

  23. Fibrinolytic therapy trialists’ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343:311–322

    Google Scholar 

  24. Grines CL, DeMaria AN (1990) Optimal utilization of thrombolytic therapy for acute myocardial infarction. Concepts and controversies. J Am Coll Cardiol 16:223–231

    Article  PubMed  CAS  Google Scholar 

  25. Gulba DC, Jost S, Daniel WG, Wagenbreth I, Lichtlen PR (1989) Intravenöse Kurzlyse bei Patienten mit therapierefraktärer instabiler Angina pectoris. In: Spannuth E, Pindur G, Wenzel E (Hrsg) Das thromboembolische Risiko und die Dysbalance der Hämostase. Schattauer, Stuttgart, S 2.23–2.35

    Google Scholar 

  26. The TIMI IIIB Investigators (1994) Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIE trial. Circulation 89:1545–1556

    Article  Google Scholar 

  27. Wilcox RG, and the LATE Trial Study Group (1992) The Late study: late assessment of thrombolytic efficacy: double-blind placebo controlled trial of Alteplase given 6-24 hours after onset of symptoms of acute myocardial infarction. (Vortrag anlässlich der XIV. Jahrestagung der European Society of Cardiology, Barcelona, 30.8.–3.9.1992)

    Google Scholar 

  28. Paolasso E (1991) EMERAS - Late streptokinase thrombolysis in acute myocardial infarction. (Vortrag anlässlich der 13. Jahrestagung der European Society of Cardiology, Amsterdam, 18.–22. August 1991)

    Google Scholar 

  29. Scholz KH, Tebbe U, Hermann C, Woijcik J, Lingen JM, Chemnitius JM (1992) Frequency of complications of cardiopulmonary resuscitation after thrombolysis during acute myocardial infarction. Am J Cardiol 69:724–728

    Article  PubMed  CAS  Google Scholar 

  30. Tenaglia AN, Califf RM, Candela RJ, Kereiakes DJ, Berrios E, Young SY (1991) Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. Am J Cardiol 68:1015–1019

    Article  PubMed  CAS  Google Scholar 

  31. Gurwitz JH, Goldberg RJ, Gore JM (1991) Coronary thrombolysis for the elderly? J Am Med Assoc 265:1720–1723

    Article  CAS  Google Scholar 

  32. Gruppo italiano per 10 studio della streptochinasi nell’infarto miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in myocardial infarction. Lancet II:397–401

    Google Scholar 

  33. ISIS-2 (Second International Study of Infarct Survival) Collaboraive Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet II:349–360

    Google Scholar 

  34. The GUSTO Investigators (1993) An international randomizid trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682

    Article  Google Scholar 

  35. The GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, venticular function, and survival after acute myocardial infarction. N Engl J Med 329:1615–1622

    Article  Google Scholar 

  36. Gruppo Italiano per 10 Studio della Sopravivenza nell’Infarto Miocardico (1990) GIS-SI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 336:65–71

    Google Scholar 

  37. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S (1993) Outcome of patients with diabetes mellitus in acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol 21:920–925

    Article  PubMed  CAS  Google Scholar 

  38. Chesebro JH, Knatterud G, Rogerts R et al. (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142–154

    Article  PubMed  CAS  Google Scholar 

  39. DeWood MA, Spores J, Nortske R, Mouser LT, Burroghs R, Golden MS, Lang HT (1980) Prevalence of total coronary occlusion during early hours of transmural myocardial infarction. N Engl J Med 303:897–902

    Article  PubMed  CAS  Google Scholar 

  40. Bode C, Smalling RW, Berg G et al. (1996) Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 94:891–898

    Article  PubMed  CAS  Google Scholar 

  41. Smalling RW, Bode C, Kalbfleisch J et al. and the RAPID Investigators (1995) More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 91:2725–2732

    Article  PubMed  CAS  Google Scholar 

  42. Gulba DC, Tanswell P, Dechend R et al. (1997) Sixty minutes alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. J Am Coll Cardiol 30:1611–1617

    Article  PubMed  CAS  Google Scholar 

  43. Antman EM, Giugliano RP, Gibons CM (1999) Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 99:2720–2732

    Article  PubMed  CAS  Google Scholar 

  44. Granger CB, White HD, Bates ER, Ohman EM, Califf RM (1994) A pooled analysis of coronary artery patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 74:1220–1228

    Article  PubMed  CAS  Google Scholar 

  45. Simes RJ, Topoi EJ, Holmes DR et al. (1995) Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Circulation 91:1923–1928

    Article  PubMed  CAS  Google Scholar 

  46. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL (1993) Impact of early perfusion status of the infarct related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 21:1391–1395

    Article  PubMed  CAS  Google Scholar 

  47. Reiner JS, Lundergan CF, Fung A et al. for the GUSTO-1 Angiographic Investigators (1996) Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. Circulation 94:2441–2446

    Article  PubMed  CAS  Google Scholar 

  48. Gruppo italiano per 10 studio della streptochinasi nell’infarto miocardico (GISSI) (1987) Long-term effects of intravenous thrombolysis in acute myocardial infarction. Final report of the GISSI Study. Lancet II:871–874

    Google Scholar 

  49. Lee DC, Mann KG (1987) The activation of human coagulation factor V by plasmin. Blood 70 [Suppl IV]:IV–100

    Google Scholar 

  50. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER (1988) Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 72/2:616–620

    Google Scholar 

  51. Ewald GA, Eisenberg PR (1995) Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 91:28–36

    Article  PubMed  CAS  Google Scholar 

  52. Fizgerald DJ, Catella F, Roy L, FitzGerald GA (1988) Marked platelet activation in vivo after streptokinase in patients with acute myocardial infarction. Circulation 77:142–150

    Article  Google Scholar 

  53. Niewiarowski S, Senyi AF, Gillies P (1973) Plasmin induced platelet aggregation and platelet release reaction. J Clin Invest 52:1647–1651

    Article  PubMed  CAS  Google Scholar 

  54. Seitz R, Pelzer H, Immel A, Egbring R (1993) Prothrombin activation by thrombolytic agents. Fibrinolysis 7:109–115

    CAS  Google Scholar 

  55. Eisenberg PR, Sherman LA, Jaffe AS (1987) Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intensive fibrinolysis. JACC 10:527–529

    Article  PubMed  CAS  Google Scholar 

  56. Eisenberg PR, Sherman L, Rich M et al. (1986) Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. JACC 7:1255–1262

    Article  PubMed  CAS  Google Scholar 

  57. Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A (1989) Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 79:980–989

    Article  PubMed  CAS  Google Scholar 

  58. Gulba DC, Barthels M, Westhoff-Bleck Met al. (1991) Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation 83:937–944

    Article  PubMed  CAS  Google Scholar 

  59. Gulba DC, Daniel WG, Simon R et al. (1990) Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty. JACC 80:1–5

    Google Scholar 

  60. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS (1985) Fibrino-peptide A: a marker of acute coronary thrombosis. Circulation 71:912–918

    Article  PubMed  CAS  Google Scholar 

  61. Gulba D, Barthels M, Reil G-H, Lichtlen P (1988) Thrombin-antithrombin-III-complex level as early predictor of reocclusion after successful thrombolysis. Lancet 2:97

    Article  PubMed  CAS  Google Scholar 

  62. Brown BG, Gallery CA, Badger RS, Kennedy JW, Mathey D, Boison EL, Dodge HT (1986) Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation 73/4:653–661

    Article  Google Scholar 

  63. Gulba DC, Bode C, Topp J, Höpp H-W, Westhoff-Bleck M, Rafflenbeul W, Lichtlen PR (1990) Die Häufigkeit von Residualthromben nach erfolgreicher Thrombolysetherapie bei akutem Herzinfarkt und ihre Bedeutung für die Rate früher Reokklusionen. Ein Bericht der multizentrischen Dosisfindungsstudie zur Thrombolysetherapie mit Urokinase-präaktivierter natürlicher Prourokinase (TCL 598). Z Kardiol 79:279–285

    PubMed  CAS  Google Scholar 

  64. Badimon L, Lassila R, Badimon J, Vallathajosula S, Chesebro JH, Fuster V (1988) Residual thrombus is more thrombogenic than severely damaged vessel wall. Circulation 78 [Suppl]:11–18

    Article  Google Scholar 

  65. Francis CW, Markham RE, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ (1983) Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 102:220–230

    PubMed  CAS  Google Scholar 

  66. Aronson DL, Chang P, Kessler CM (1992) Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation 85:1706–17l2

    Article  PubMed  CAS  Google Scholar 

  67. Bennett MR, Evan GI, Newby AC (1994) Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-Y, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ Res 74:525–536

    Article  PubMed  CAS  Google Scholar 

  68. Marder VJ (1983) Pharmacology of thrombolytic agents: implications for therapy of coronary artery thrombosis. Circulation 68 [Suppl 1]:I-2-I-5

    Google Scholar 

  69. Sharma GVRK, Cella G, Parisi AF, Sasahara AA (1982) Thrombolytic therapy. N Engl J Med 306:1268–1276

    Article  PubMed  CAS  Google Scholar 

  70. Marder VJ, Sherry S (1988) Thrombolytic therapy: current status (first of two parts). N Engl J Med 318:1512–1520

    Article  PubMed  CAS  Google Scholar 

  71. Barthels M, Gulba D, Engel MJ (1985) Systemic fibrinolysis as an effect of intracoronary thrombolysis. In: Davidson JF, Donati MB, Cocchieri S (eds): Progress in fibrinolysis VII. Churchill Livingstone, Edinburgh, pp 49–51

    Google Scholar 

  72. Verstraete M, Bernard R, Bory MD et al. (1985) Randomised trial of intravenous recombinant tissue-type plasminogen activator versus streptokinase in acute myocardial infarction. Lancet 1:842–847

    Article  PubMed  CAS  Google Scholar 

  73. PRIMI Trial Study Group (1989) Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1:863–868

    Google Scholar 

  74. Neuhaus KL, Tebbe U, Gottwik M et al. (1988) Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German activator urokinase study (GAUS). JACC 12:581–587

    Article  PubMed  CAS  Google Scholar 

  75. Gulba DC, Fischer K, Barthels M et al. (1989) Potentiative effect of heparin in thrombolytic therapy of evolving myocardial infarction with natural pro-urokinase. Fibrinolysis 3:165–173

    Google Scholar 

  76. Topol EJ, George BS, Kereiakes DJ et al. and the TAMI Study Group (1989) A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarkt ion. Circulation 79:281–286

    Article  PubMed  CAS  Google Scholar 

  77. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the HeparinAspirinReperfusion Trial (HART) Investigators (1990) A comparison between heparinand low-dose aspirin as adjunctive therapy with tissue plasminogen activator foracute myocardial infarction. N Engl J Med 323:1433-1437

    Google Scholar 

  78. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL (1990) Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 66:1412–1417

    Article  PubMed  CAS  Google Scholar 

  79. DeBono DP, Simoons ML, Tijsen J et al. for the European Cooperative Study Group (1992) Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 67:122–128

    Article  CAS  Google Scholar 

  80. Hsia J, Kleimann NS, Aguirre F, Chaitman BR, Roberts R, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators (1992) Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol 20:513–519

    Article  Google Scholar 

  81. Meijer A, Verheugt FW, Werter CJ, Lie KI, van der Pol JM, van Eenige MJ (1993) Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study: results of the APRICOT Study. Circulation 87:1524–1530

    Article  PubMed  CAS  Google Scholar 

  82. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by abntithrombin III-independent inhibitors. J Clin Invest 86:385–391

    Article  PubMed  CAS  Google Scholar 

  83. Cannon CP, McCabe CH, Henry TD et al. (1994) A pilot trial of recombinant desulfato-hirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 23:993–1003

    Article  PubMed  CAS  Google Scholar 

  84. Lee V (1995) Initial Experience with Hirudin and Streptokinase in Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 6 Trial. Am J Cardiol 75:7–13

    Article  PubMed  CAS  Google Scholar 

  85. Antman EM, for the TIMI 9 A Investigators (1994) Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9 A trial. Circulation 90:1624–1630

    Article  PubMed  CAS  Google Scholar 

  86. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators (1994) Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631–1637

    Article  Google Scholar 

  87. Neuhaus KL, Essen R von, Tebbe U et al. (1994) Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 90:1638–1642

    Article  PubMed  CAS  Google Scholar 

  88. Antman E (1996) Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 94:911–921

    Article  PubMed  CAS  Google Scholar 

  89. 89. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775–782

    Article  Google Scholar 

  90. Verstraete M, Zoldhelyi P: Novel antithrombotic drugs in development. Drugs 1995 49:856–884

    Article  PubMed  CAS  Google Scholar 

  91. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K (1995) Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 130:877–892

    Article  PubMed  CAS  Google Scholar 

  92. Windstetter U, Huber K, Gulba DC (1997) New antithrombotic agents: an overview. Fibrinolysis and Proteolysis 11 [Suppl 1]:85–96

    Google Scholar 

  93. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LI, Cigarroa, J.E., Palacios IF, Leinbach RC (1997) Restoration of coronary fiow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activator. Circulation 95:1755–1759

    Google Scholar 

  94. Van den Brand M, Laarman GJ, Steg PG et al. (1999) Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographie results from the CAPTURE trial. Eur Heart J 20:1572–1578

    Article  PubMed  Google Scholar 

  95. Yasada T, Gold HK, Leinbach RC (1990) Lysis of plasminogen activator resistant platelet rieh coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GP IIb/IIIa antibody. J Am Coll Cardiol 16:1728–1735

    Article  Google Scholar 

  96. Ohman EM, Kleiman NS, Gacioch G et al. for the IMPACT-AMI Investigators (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled dose-ranging trial. Circulation 95:846–854

    Article  PubMed  CAS  Google Scholar 

  97. 97. The GUSTO V Investigators (2001) Repefusion therapy or acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Iib/iia inhibition: the GUSTO V radnomied trial. Lancet 357:1905–1914

    Article  Google Scholar 

  98. Marder VJ, Shulmann NR (1969) High molecular weight derivatives ofhuman fibrinogen produced by plasmin. II. Mechanisms of their anticoagulant activity. J Biol Chem 244:2120–2124

    PubMed  CAS  Google Scholar 

  99. Fletcher AP, Alkjaersig N, Sherry S (1962) Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J Clin Invest 41:896–916

    Article  PubMed  CAS  Google Scholar 

  100. Dechend R, Thode H, Müller T, Eisert WE, Gulba DC (1994) Fragmentation pattern of fibrinogen during thrombolysis in acute myocardial infarction with fibrin-specific plasminogen activators - detection of high-molecular weight fibrinogen degradadion products. Fibrinolysis 8 [Suppl 11]:102–104

    Google Scholar 

  101. Sawyer WD, Alkjaersig N, Fletcher AP, Sherry S (1960) Comparison of fibrinolytic and fibrinogenolytic effects of plasminogen activators and proteolytic enzymes in plasma. Thromb Diath Haemorrhag 5:149–191

    CAS  Google Scholar 

  102. Fletcher AP, Alkjaersig N, Fisher S, Sherry S (1966) The proteolysis of fibrinogen by plasmin: the identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally. J Lab Clin Med 68:780–802

    PubMed  CAS  Google Scholar 

  103. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS (1989) Bleeding during thrombolytic therapy for acute myocardial infarction: Mechanisms and management. Ann Intern Med 111:1010–1022

    PubMed  CAS  Google Scholar 

  104. Califf RM, Fortin DF, Tenaglia AN, Sane DC (1992) Clinical risks of thrombolytic therapy. Am J Cardiol 69 [Suppl]:12A–20A

    Article  PubMed  CAS  Google Scholar 

  105. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, Van Domburg R, Boersma E, Franzosi MG, Califf RM, Schröder R, Braunwald E (1993) Individual risk assement for intracranial haemorrhage during thrombolytic therapy. Lancet 342:1523–1528

    Article  PubMed  CAS  Google Scholar 

  106. Kingston IB, Castro MJM, Andersonb S (1995) In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid b-peptide analogues. Nat Med 1:138–142

    Article  PubMed  CAS  Google Scholar 

  107. Jalihal S, Morris GK (1990) Antistreptokinase titres after intravenous streptokinase. Lancet 335:184–185

    Article  PubMed  CAS  Google Scholar 

  108. Collen D, de Cook F, Vanlinthout I, Declerck PJ, Lijnen HR, Stassen JM (1992) Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 6:232–242

    CAS  Google Scholar 

  109. Gulba DC, Bode C, Runge MS, Huber K (1998) Thrombolytic agents - an updated overview. Fibrinol Proteol 12 [Suppl 2]:39–58

    Article  CAS  Google Scholar 

  110. Boissei JP, Castaigne A, Mercier C, Lion L, Leizorovicz A (1996) Ventricular fibrillation following administration of thrombolytic treatment. The EMIP (European Myocardial Infarction Project) experience. Eur Heart J 17:213–221

    Article  Google Scholar 

  111. Goldberg S, Greenspon AJ, Urban PL, Muza B, Berger B, Walinsky P, Maroko PR (1983) Reperfusion arrythmias: a marker of restoration of antegrade flow during intracoronary thrombolysis for acute myocardial infarction. Am Heart J 105:26–32

    Article  PubMed  CAS  Google Scholar 

  112. Wei YJ, Markis JE, Malagold M, Braunwald E (1983) Cardiovascular reflexes stimulated by reperfusion of ischemic myocardium in acute myocardial infarction. Circulation 67:769–801

    Article  Google Scholar 

  113. Ross AM, Coyne KS, Reiner JS et al. for the PACT Investigators (1999) A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediated planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol 34:195461962

    Article  Google Scholar 

  114. Böttiger BW, Bode C, Kern S, Gries A, Gust R, Glätzer R, Bauer H, Motsch J, Martin E: Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 357:1583–1585

    Google Scholar 

Download references

Authors
  1. Angelika Kusch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Lankes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dietrich C. Gulba
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinikum Benjamin Franklin Med. Klinik II, Kardiopulmologie, Freie Universität Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

    Hans-Richard Arntz

  2. Med. Klinik I, Krankenhaus Düren, Roonstr. 30, 52351, Düren, Germany

    Dietrich C. Gulba

  3. Med. Klinik II, Klinikum Lippe GmbH, Röntgenstr.18, 32756, Detmold, Germany

    Ulrich Tebbe

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kusch, A., Lankes, W., Gulba, D.C. (2002). Thrombolysetherapie des akuten Herzinfarktes. In: Arntz, HR., Gulba, D.C., Tebbe, U. (eds) Notfallbehandlung des akuten Koronarsyndroms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56220-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56220-4_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41367-7

  • Online ISBN: 978-3-642-56220-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation